Albion Financial Group UT Acquires 2,669 Shares of The Clorox Company (NYSE:CLX)

Albion Financial Group UT raised its stake in The Clorox Company (NYSE:CLX - Free Report) by 8.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,774 shares of the company's stock after buying an additional 2,669 shares during the period. Albion Financial Group UT's holdings in Clorox were worth $5,121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Redwood Park Advisors LLC bought a new stake in shares of Clorox during the fourth quarter worth about $26,000. Millstone Evans Group LLC acquired a new position in shares of Clorox during the fourth quarter worth $31,000. Wood Tarver Financial Group LLC bought a new stake in shares of Clorox in the fourth quarter worth $31,000. GKV Capital Management Co. Inc. acquired a new position in shares of Clorox in the fourth quarter worth approximately $32,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Clorox in the 4th quarter valued at $33,000. Institutional investors own 78.53% of the company's stock.

Clorox Trading Up 2.8%

Shares of NYSE CLX traded up $3.42 during midday trading on Tuesday, hitting $123.49. 2,341,382 shares of the company traded hands, compared to its average volume of 1,393,663. The Clorox Company has a 12-month low of $117.35 and a 12-month high of $171.37. The stock has a 50-day moving average price of $130.83 and a 200 day moving average price of $144.69. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The firm has a market cap of $15.22 billion, a P/E ratio of 22.17, a P/E/G ratio of 2.72 and a beta of 0.51.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period last year, the firm posted $1.71 earnings per share. The company's revenue was down 8.0% compared to the same quarter last year. As a group, analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Insiders Place Their Bets

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, with a total value of $546,280.00. Following the transaction, the director owned 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.57% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently commented on CLX. Evercore ISI set a $140.00 target price on Clorox and gave the stock an "underperform" rating in a research note on Tuesday, May 6th. Jefferies Financial Group cut their target price on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. UBS Group dropped their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Wells Fargo & Company reduced their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays reduced their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $149.50.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.